Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05345327
PHASE3

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Sponsor: The George Institute

View on ClinicalTrials.gov

Summary

The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

994

Start Date

2023-01-01

Completion Date

2026-06-30

Last Updated

2024-12-20

Healthy Volunteers

No

Conditions

Interventions

DRUG

Dapagliflozin

SGLT2 inhibitor

DRUG

Metformin

Metformin

Locations (8)

The George Institute for Global Health

Sydney, New South Wales, Australia

The George Institute for Global Health

Brisbane, Queensland, Australia

Monash University

Melbourne, Victoria, Australia

National Hospital - Galle

Galle, Southern Province, Sri Lanka

National Hospital of Sri Lanka 1

Colombo, Sri Lanka

National Hospital of Sri Lanka 2

Colombo, Sri Lanka

Jaffna Teaching Hospital

Jaffna, Sri Lanka

Kandy National Hospital

Kandy, Sri Lanka